Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The renal nerves comprise a complex network of efferent sympathetic and afferent sensory fibers that innervate the kidneys, primarily traveling within the adventitia of the renal arteries. The efferent fibers regulate key physiological processes including the stimulation of renin release from juxtaglomerular cells, the promotion of tubular sodium and water reabsorption, and the modulation of renal vascular resistance [1][3]. Conversely, afferent renal nerves transmit sensory information regarding renal ischemia, stretch, and chemical changes back to the central nervous system, which can trigger a systemic increase in sympathetic outflow [2]. In pathological states such as resistant hypertension and chronic heart failure, the renal nerves often exhibit chronic hyperactivity, driving a vicious cycle of sympathetic overstimulation and fluid retention. While traditionally managed with sympatholytic drugs that inhibit neurotransmitter release or receptor binding, the renal nerves have become a primary target for catheter-based renal denervation (RDN) therapies. These procedures use radiofrequency or ultrasound energy to ablate the nerves, effectively lowering blood pressure and reducing sympathetic drive in patients who do not respond to conventional pharmacological interventions [3][4]. [1] DiBona, G. F. (2000). 'Physiology in health and disease: The functions of the renal nerves'. Rev Physiol Biochem Pharmacol. [2] Schlaich, M. P., et al. (2009). 'Renal denervation as a therapeutic approach'. Hypertension. [3] StatPearls (2023). 'Renal Denervation'. [4] Kandzari, D. E., et al. (2022). 'The SPYRAL HTN-ON MED Trial'. The Lancet.
The renal nerves act as a pathway for sympathetic communication between the central nervous system and the kidneys. Therapeutic intervention, primarily through renal denervation (RDN) procedures or sympatholytic drugs, aims to interrupt efferent signaling to reduce renin release and sodium retention, and afferent signaling to decrease global sympathetic vasomotor tone [1][2].
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Renal sympathetic nerves (RSN).